drugset / Trial / NCT00543023

A Study of the Treatment of Postmenopausal Women With Osteoporosis

NCT00543023

Phase 3 Completed 104 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the effect of treatment with teriparatide with that of salmon calcitonin in postmenopausal women with osteoporosis.

Timeline

Start
2003-06
Primary completion
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic 20 ug Subcutaneous
Comparator salmon calcitonin Unknown 100 iu Subcutaneous